QUEST DIAGNOSTICS INC【DGX】
時価総額
$228.1億
PER
臨床検査・診断情報サービスの米国最大手。幅広い検査メニューとデータ駆動の診断ITソリューションを展開。2023年に腫瘍検査企業を3.92億ドルで買収、2024年に病院系ラボを計6.83億ドルで買収。米国中心にカナダも含め全国展開、90%超の被保険者にアクセス。
| 2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Cash and cash equivalents | 449 | 165 | 296 | 187 | 192 | 133 | 359 | 137 | 135 | 1,192 | 1,158 | 872 | 315 | 686 | 549 |
| Accounts Receivable, after Allowance for Credit Loss, Current | 845 | 906 | 867 | 852 | 932 | 901 | 926 | 924 | 1,012 | 1,063 | 1,520 | 1,438 | 1,195 | 1,210 | 1,304 |
| Inventories | 77 | 89 | 93 | 91 | 110 | 84 | 82 | 95 | 99 | 123 | 223 | 208 | 192 | 190 | 188 |
| Prepaid expenses and other current assets | - | - | 91 | 105 | 200 | 207 | 155 | 150 | 144 | 112 | 157 | 223 | 196 | 286 | 351 |
| Total current assets | 1,605 | 1,401 | 1,561 | 1,383 | 1,603 | 1,501 | 1,531 | 1,306 | 1,390 | 2,490 | 3,058 | 2,741 | 1,898 | 2,372 | 2,392 |
| Property, plant and equipment, net | 834 | 800 | 756 | 805 | 933 | 925 | 1,029 | 1,145 | 1,288 | 1,453 | 1,627 | 1,707 | 1,766 | 1,816 | 2,113 |
| Operating lease right-of-use assets | - | - | - | - | - | - | - | - | - | 518 | 604 | 597 | 585 | 602 | 651 |
| Goodwill | 5,102 | 5,796 | 5,536 | 5,649 | 6,032 | 5,905 | 6,000 | 6,335 | 6,563 | 6,619 | 6,873 | 7,095 | 7,220 | 7,733 | 8,856 |
| Intangible assets, net | 796 | 1,036 | 872 | 896 | 1,071 | 984 | 949 | 1,119 | 1,207 | 1,121 | 1,167 | 1,167 | 1,092 | 1,166 | 1,763 |
| Equity Method Investments | - | - | - | - | - | 473 | 443 | 462 | 436 | 482 | 521 | 141 | 132 | 135 | 123 |
| Other assets | 189 | 281 | 205 | 215 | 238 | 174 | 148 | 136 | 119 | 160 | 176 | 163 | 144 | 198 | 255 |
| Total assets | 8,528 | 9,313 | 9,284 | 8,948 | 9,877 | 9,962 | 10,100 | 10,503 | 11,003 | 12,843 | 14,026 | 13,611 | 12,837 | 14,022 | 16,153 |
| Accounts payable and accrued expenses | 865 | 907 | 1,016 | 920 | 1,191 | 1,014 | 975 | 1,021 | 1,021 | 1,041 | 1,633 | 1,600 | 1,396 | 1,359 | 1,394 |
| Long-Term Debt, Current Maturities | 349 | - | - | - | - | - | - | - | 464 | 804 | 2 | 2 | 2 | 303 | 602 |
| Operating Lease, Liability, Current | - | - | - | - | - | - | - | - | - | 145 | 141 | 151 | 153 | 153 | 173 |
| Total current liabilities | 1,214 | 1,561 | 1,048 | 1,132 | 1,709 | 1,173 | 981 | 1,057 | 1,485 | 1,990 | 1,776 | 1,753 | 1,551 | 1,815 | 2,169 |
| Long-term debt | 2,641 | 3,371 | 3,354 | 3,120 | 3,244 | 3,492 | 3,728 | 3,748 | 3,429 | 3,966 | 4,013 | 4,010 | 3,978 | 4,410 | 5,615 |
| Long-term operating lease liabilities | - | - | - | - | - | - | - | - | - | 413 | 499 | 494 | 489 | 503 | 535 |
| Other liabilities | 618 | 667 | 636 | 723 | 594 | 514 | 654 | 663 | 745 | 711 | 847 | 792 | 812 | 876 | 938 |
| Redeemable noncontrolling interest | - | - | - | - | - | - | - | 80 | 77 | 76 | 82 | 79 | 77 | 76 | 83 |
| Common Stock, Value, Issued | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Additional paid-in capital | 2,311 | 2,348 | 2,371 | 2,379 | 2,418 | 2,481 | 2,545 | 2,612 | 2,667 | 2,722 | 2,841 | 2,260 | 2,295 | 2,320 | 2,361 |
| Retained earnings | 3,867 | 4,264 | 4,690 | 5,358 | 5,723 | 6,199 | 6,613 | 7,138 | 7,602 | 8,174 | 9,303 | 7,649 | 8,290 | 8,825 | 9,360 |
| Accumulated other comprehensive loss | 11 | -8 | 14 | -8 | -27 | -38 | -72 | -48 | -59 | -39 | -21 | -14 | -21 | -14 | -88 |
| Treasury stock, at cost; 51 shares as of both December 31, 2024 and 2023 | -2,158 | 2,912 | 2,914 | 3,783 | 3,815 | 3,960 | 4,460 | 4,783 | 4,996 | 5,218 | 5,366 | 3,453 | 4,673 | 4,826 | 4,857 |
| Total Quest Diagnostics stockholders’ equity | 4,054 | 3,715 | 4,186 | 3,973 | 4,330 | 4,713 | 4,660 | 4,955 | 5,267 | 5,687 | 6,809 | 6,483 | 5,930 | 6,342 | 6,813 |
| Noncontrolling interests | 21 | 22 | 23 | 25 | 29 | 29 | 32 | 34 | 51 | 46 | 50 | 39 | 37 | 35 | 35 |
| Total stockholders’ equity | 4,054 | 3,715 | 4,186 | 3,973 | 4,330 | 4,713 | 4,660 | 4,955 | 5,267 | 5,687 | 6,809 | 6,483 | 5,930 | 6,342 | 6,813 |
| Total liabilities and stockholders’ equity | 8,528 | 9,313 | 9,284 | 8,948 | 9,877 | 9,962 | 10,100 | 10,503 | 11,003 | 12,843 | 14,026 | 13,611 | 12,837 | 14,022 | 16,153 |